All data are based on the daily closing price as of December 24, 2024
a

Adimmune

4142.TW
0.61 USD
0.01
+1.67%

Overview

Last close
0.61 usd
Market cap
255.20M usd
52 week high
1.15 usd
52 week low
0.59 usd
Target price
0.7 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
5.1145
Price/Book Value
1.5715
Enterprise Value
277.95M usd
EV/Revenue
5.784
EV/EBITDA
25.0412

Key financials

Revenue TTM
50.66M usd
Gross Profit TTM
14.19M usd
EBITDA TTM
-14.72M usd
Earnings per Share
-0.04 usd
Dividend
N/A usd
Total assets
8.72B usd
Net debt
453.89M usd

About

Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
  • Symbol
    4142.TW
  • Exchange
    TW
  • Isin
    TW0004142005
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Chi-Hsien Chan
  • Headquarter
    Taichung
  • Web site
    https://www.adimmune.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top